IOVA (Iovance Biotherapeutics) EPS (Basic): $-0.95 (TTM As of Mar. 2026)


IOVA Iovance Biotherapeutics Inc IOVA
44 GF Score
Price $4.21
GF Value $18.83
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Iovance Biotherapeutics EPS (Basic)?

Iovance Biotherapeutics IOVA -0.94% 44 EPS (Basic) is $-0.95 as of Mar. 2026. GuruFocus rates IOVA with a GF Score™ of 44/100 and a GF Value™ of $18.83 (Possible Value Trap). The stock has 2 warning signs investors should review.

Iovance Biotherapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $-0.19. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.95.

Iovance Biotherapeutics's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.19. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.95.

Iovance Biotherapeutics's EPS without NRI for the three months ended in Mar. 2026 was $-0.19. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.94.

During the past 3 years, the average EPS without NRI Growth Rate was 24.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 12.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was -8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Iovance Biotherapeutics's highest 3-Year average EPS without NRI Growth Rate was 76.30% per year. The lowest was -229.90% per year. And the median was -15.65% per year.

Iovance Biotherapeutics  (NAS:IOVA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Iovance Biotherapeutics EPS (Basic) Related Terms

Iovance Biotherapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Iovance Biotherapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iovance Biotherapeutics EPS (Basic) Chart

Iovance Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.23 -2.49 -1.89 -1.28 -1.09

Iovance Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.36 -0.33 -0.25 -0.18 -0.19
IOVA
44GF Score
Iovance Biotherapeutics Inc IOVA
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Iovance Biotherapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Iovance Biotherapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-390.978-0)/357.345
=-1.09

Iovance Biotherapeutics's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-79.045-0)/418.511
=-0.19

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-0.95 mean?
Iovance Biotherapeutics (IOVA) has a EPS (Basic) of $-0.95 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Iovance Biotherapeutics and its competitors.
Is Iovance Biotherapeutics' EPS (Basic) too high?
Iovance Biotherapeutics' current EPS (Basic) is $-0.95. Overall, Iovance Biotherapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' EPS (Basic) compare to HRMY and NRIX?
Iovance Biotherapeutics' EPS (Basic) of $-0.95 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Iovance Biotherapeutics and its competitors. Iovance Biotherapeutics's current EPS (Basic) is $-0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Iovance Biotherapeutics (IOVA) is currently considered Possible Value Trap. The stock's GF Value™ is $18.83, compared to a current price of $4.21 — trading 77.7% below its estimated fair value. The current EPS (Basic) is $-0.95. Iovance Biotherapeutics' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Iovance Biotherapeutics (IOVA), the current EPS (Basic) is $-0.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Iovance Biotherapeutics (IOVA) Overvalued in 2026?

Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued. The current stock price of $4.21 is trading 77.7% below its estimated GF Value™ of $18.83. GuruFocus considers Iovance Biotherapeutics to be Possible Value Trap.

Key valuation signals for IOVA:

  • EPS (Basic): $-0.95
  • GF Value™: $18.83 vs. price of $4.21 (77.7% below fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the IOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Iovance Biotherapeutics Business Description

Address 825 Industrial Road, Suite 100, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
44GF Score

Get the complete analysis for IOVA

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.21
Price
$18.83
GF Value